AstraZeneca PLC (AZN.LN) said Monday that a phase 3 trial of a three-drug combination for the treatment of chronic obstructive pulmonary disease met eight out of its main objectives.
The Anglo-Swedish pharmaceutical company said that the results of the Kronos trial, which compared a combination of budesonide, glycopyrronium and formoterol with a number of rival therapies, was published in the journal The Lancet Respiratory Medicine.
The three-drug cocktail called PT010 showed a significant reduction of exacerbations in patients with the disease compared with rival therapy, the company said.
AstraZeneca said it plans on making a first regulatory submission for the drug in the second half of the year.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.